AVXL · XBRL financial data

Anavex Life Sciences financial statements, every fiscal year

The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (AVXL's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Research and development	25,232	32,984	37,916	43,717	41,838	37,592
Selling, general and administrative	—	—	—	12,046	11,039	13,816
General and administrative	5,857	9,018	13,070	12,039	11,039	13,816
Total operating expenses	31,088	42,001	(50,986)	55,756	52,877	51,408
Operating income (loss)	(31,088)	(42,002)	(50,986)	(55,756)	(52,877)	(51,408)
Net income (loss)	(26,280)	(37,909)	(47,978)	(47,505)	(43,002)	(46,377)
Earnings per share, basic USD per share	—	(0.54)	(0.62)	(0.60)	(0.52)	(0.54)
Earnings per share, diluted USD per share	—	(0.54)	(0.62)	(0.60)	(0.52)	(0.54)
Weighted average shares, basic thousands of shares	—	69,803	76,910	79,788	83,468	85,289
Weighted average shares, diluted thousands of shares	—	69,803	76,910	79,788	83,468	85,289

Fiscal years (AVXL's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Cash and cash equivalents	29,249	152,108	149,158	151,024	132,187	102,577
Prepaid and other current assets	—	372	354	653	931	429
Total assets	34,542	161,616	152,705	154,386	135,567	103,815
Accounts payable	3,989	4,740	3,825	4,322	9,627	4,249
Accrued liabilities	3,317	5,615	5,945	7,295	4,835	3,892
Total current liabilities	7,306	10,798	—	—	—	—
Total liabilities	7,306	10,798	10,214	12,534	15,304	8,946
Accumulated deficit	(159,677)	(197,586)	(245,564)	(293,069)	(336,071)	(382,448)
Total stockholders' equity	27,237	150,818	142,491	141,852	120,263	94,869
Total liabilities and equity	34,542	161,616	152,705	154,386	135,567	103,815
Common shares outstanding (cover page) thousands of shares	66,963	76,018	77,962	82,087	84,816	89,348

Fiscal years (AVXL's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Net income (loss)	(26,280)	(37,909)	(47,978)	(47,505)	(43,002)	(46,377)
Stock-based compensation	4,877	8,231	18,379	16,370	9,438	11,549
Net cash from operating activities	(21,287)	(30,384)	(24,238)	(27,785)	(30,812)	(39,044)
Proceeds from issuing common stock	28,754	153,219	20,985	27,875	11,284	—
Net cash from financing activities	28,350	153,242	21,288	29,651	11,975	9,434

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Anavex Life Sciences	118,326	not reported	(9,096)*	92.7M	13.0 quarters	Q3 FY26 10-QJun 30, 2026
ImmunityBio	75,670	51,240	(66,494)*	1.1B	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Immunome	217,706	0	(61,692)*	113.6M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Pacira BioSciences	205,875	192,399	57,460*	39.9M	—	Q2 FY26 10-QJun 30, 2026
Phibro Animal Health	75,548	386,774	26,082	not reported	—	Q1 FY27 10-QSep 30, 2026
uniQure	98,442	5,196	(47,827)*	70.1M	2.6 quarters	Q3 FY26 10-QSep 30, 2026
Cogent Biosciences	181,172	not reported	(77,271)*	173.5M	10.3 quarters	Q2 FY26 10-QJun 30, 2026
Anaptysbio	133,826	27,488*	(26,640)*	29.9M	6.2 quarters	Q4 FY26 10-KTJun 30, 2026
Amphastar Pharmaceuticals	223,614	183,903	51,324*	42.5M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.